Europe

- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation

MOR208 (L-MIND): Interim data from phase 2 L-MIND study of MOR208 plus lenalidomide in 81 patients with relapsed/refractory DLBCL accepted for oral presentation

First commercially available reference standard for microsatellite instability (MSI) testing

Unique technology set to play a key role in the rapidly emerging gene therapy market

Facilities in The Schrödinger Building to bring together AI experts and biologists

Researchers at the University of Eastern Finland have developed novel antibacterial compounds, focusing on the role of LsrK kinase. LsrK kinase is a protein involved in bacterial communication.

MC Services AG announced today that it will support, as a media partner, the 24th annual BIO-Europe® 2018, Europe’s largest partnering conference for the global biotechnology industry.

Epigenomics AG today announced the Veterans Administration - New York Harbor Healthcare System (VA-Manhattan) is commencing a study to assess the adherence impact of offering a blood-based colorectal cancer screening test and colonoscopy completion in patients who have refused colonoscopy and fecal immunochemical test (FIT).

Galapagos NV reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF).

Karolinska Development announces today top line results from a Phase 2b study with tafoxiparin in treatment of protracted labor. The results show that the study did not achieve its primary endpoint of reducing the time to vaginal delivery through treatment with tafoxiparin. Karolinska Development will revalue the portfolio company’s book value, which is expected to negatively impact the result by SEK 40 million for the fourth quarter of 2018.